Compare REAL & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | ZURA |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 455.4M |
| IPO Year | 2019 | 2021 |
| Metric | REAL | ZURA |
|---|---|---|
| Price | $8.91 | $4.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $18.00 | $18.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.5M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $692,845,000.00 | N/A |
| Revenue This Year | $14.82 | N/A |
| Revenue Next Year | $11.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $8.05 | $3.15 |
| 52 Week High | $17.39 | $7.25 |
| Indicator | REAL | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 31.52 | 32.37 |
| Support Level | $8.70 | $3.90 |
| Resistance Level | $9.95 | $5.87 |
| Average True Range (ATR) | 0.39 | 0.29 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 22.60 | 18.75 |
The RealReal Inc is an online marketplace for authenticated, resale luxury goods, providing an end-to-end service that unlocks supply and creates a trusted, curated marketplace for buyers globally. Since its inception, the company has cultivated a loyal and engaged consignor and buyer base through continuous investment in its technology platform, logistics infrastructure, brand and people. It offers a wide selection of authenticated, mainly pre-owned luxury goods bearing the brands of thousands of luxury and premium designers, including Cartier, Chanel, Christian Dior, Gucci, Hermes, Louis Vuitton and Rolex. The company offers products across women's fashion, men's fashion, jewelry, and watches, promoting the recirculation of luxury goods and contributing to a more sustainable world.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.